更正：杜氏利什曼原虫重组NAD依赖性SIR-2蛋白：作为抗内脏利什曼病潜在疫苗的免疫生化特性
Correction: Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
作者信息
Baharia Rajendra K, Tandon Rati, Sharma Tanuj, Suthar Manish K, Das Sanchita, Siddiqi Mohammad Imran, Saxena Jitendra Kumar, Sundar Shyam, Dube Anuradha
出版信息
PLoS Negl Trop Dis. 2015 Apr 22;9(4):e0003742. doi: 10.1371/journal.pntd.0003742. eCollection 2015 Apr.
Abstract
[This corrects the article DOI: 10.1371/journal.pntd.0003557.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pntd.0003557。]
相似文献
1
Correction: Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.更正：杜氏利什曼原虫重组NAD依赖性SIR-2蛋白：作为抗内脏利什曼病潜在疫苗的免疫生化特性
PLoS Negl Trop Dis. 2015 Apr 22;9(4):e0003742. doi: 10.1371/journal.pntd.0003742. eCollection 2015 Apr.
2
Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.一种预防性杜氏利什曼原虫DNA疫苗对内脏型和皮肤型鼠利什曼病的交叉保护效力。
Infect Immun. 2005 Feb;73(2):812-9. doi: 10.1128/IAI.73.2.812-819.2005.
3
Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis.杜氏利什曼原虫：针对重组鸟氨酸脱羧酶蛋白的细胞免疫反应受损，这可能是利什曼原虫在内脏利什曼病中的一种逃避策略。
Int J Parasitol. 2015 Jan;45(1):33-42. doi: 10.1016/j.ijpara.2014.08.013. Epub 2014 Oct 15.
4
Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.DNA 和蛋白质利什曼原虫γ-谷氨酰半胱氨酸合成酶疫苗对预防大疱性皮肤利什曼病或墨西哥利什曼原虫感染引起的小鼠皮肤利什曼病的交叉保护作用的比较评估。
Vaccine. 2012 Feb 8;30(7):1357-63. doi: 10.1016/j.vaccine.2011.12.067. Epub 2011 Dec 28.
5
Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis.重新审视利什曼化：用源自斯里兰卡的天然减毒皮肤利什曼原虫分离株进行免疫接种可预防内脏利什曼病。
Vaccine. 2013 Feb 27;31(10):1420-5. doi: 10.1016/j.vaccine.2012.11.065. Epub 2012 Dec 7.
6
Correction: High accuracy of an ELISA test based in a flagella antigen of Leishmania in serodiagnosis of canine visceral leishmaniasis with potential to improve the control measures in Brazil-A Phase II study.更正：基于利什曼原虫鞭毛抗原的ELISA检测在犬内脏利什曼病血清学诊断中的高准确性及其在巴西改善控制措施的潜力——一项II期研究
PLoS Negl Trop Dis. 2020 May 20;14(5):e0008346. doi: 10.1371/journal.pntd.0008346. eCollection 2020 May.
7
Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.杜氏利什曼原虫p36（LACK）DNA疫苗具有高度免疫原性，但对实验性内脏利什曼病无保护作用。
Infect Immun. 2001 Aug;69(8):4719-25. doi: 10.1128/IAI.69.8.4719-4725.2001.
8
Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.生长停滞的利什曼原虫无鞭毛体的产生：一种开发抗内脏利什曼病减毒活疫苗候选株的工具。
Vaccine. 2014 Jun 30;32(31):3895-901. doi: 10.1016/j.vaccine.2014.05.009. Epub 2014 May 14.
9
Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.用编码杜氏利什曼原虫蛋白磷酸糖N端结构域的DNA进行免疫接种，可产生针对实验性内脏利什曼病的Th1型免疫保护反应。
J Immunol. 2009 Jul 1;183(1):470-9. doi: 10.4049/jimmunol.0900265.
10
Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.利什曼原虫基因组分析与高通量免疫筛选确定图津蛋白为抗内脏利什曼病的新型疫苗候选物。
Vaccine. 2014 Jun 24;32(30):3816-22. doi: 10.1016/j.vaccine.2014.04.088. Epub 2014 May 9.
本文引用的文献
1
Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.杜氏利什曼原虫重组NAD依赖型SIR-2蛋白：作为抗内脏利什曼病潜在疫苗的免疫生化特性
PLoS Negl Trop Dis. 2015 Mar 6;9(3):e0003557. doi: 10.1371/journal.pntd.0003557. eCollection 2015 Mar.
Zotero 插件